Pilot screening study of targeted genetic polymorphisms for association with seasonal influenza hospital admission

Journal of Medical Virology

Volumn 90, Issue 3, 2018, Pages 436-446

  Carter, Tonia C ^a   Hebbring, Scott J ^a   Liu, Jixia ^a   Mosley, Jonathan D ^b   Shaffer, Christian M ^b   Ivacic, Lynn C ^a   Kopitzke, Sarah ^a   Stefanski, Elisha L ^a   Strenn, Rob ^a   Sundaram, Maria E ^a   Meece, Jennifer ^a   Brilliant, Murray H ^a   Ferdinands, Jill M ^c   Belongia, Edward A ^a  

^a MARSHFIELD CLINIC   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

host susceptibility; IFITM3; influenza; polymorphisms; virus

Indexed keywords

IFITM3 PROTEIN, HUMAN; MEMBRANE PROTEIN; RNA BINDING PROTEIN;

ADULT; AGED; CASE CONTROL STUDY; ELECTRONIC HEALTH RECORD; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETIC VARIATION; GENETICS; GENOTYPE; HOSPITALIZATION; HUMAN; INFLUENZA; INFLUENZA A VIRUS (H1N1); MALE; MIDDLE AGED; PILOT STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; CASE-CONTROL STUDIES; ELECTRONIC HEALTH RECORDS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENETIC VARIATION; GENOTYPE; HOSPITALIZATION; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PILOT PROJECTS; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA-BINDING PROTEINS;

EID: 85033572319     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.24975     Document Type: Article

References (40)

1. Srivastava B, Blazejewska P, Hessmann M, et al. Host genetic background strongly influences the response to influenza a virus infections. PLoS ONE. 2009; 4:e4857.
2. Boon AC, Finkelstein D, Zheng M, et al. H5N1 influenza virus pathogenesis in genetically diverse mice is mediated at the level of viral load. MBio. 2011; 2:e00171–e00111.
3. Everitt AR, Clare S, Pertel T, et al. IFITM3 restricts the morbidity and mortality associated with influenza. Nature. 2012; 484:519–523.
4. Brass AL, Huang IC, Benita Y, et al. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell. 2009; 139:1243–1254.
5. Feeley EM, Sims JS, John SP, et al. IFITM3 inhibits influenza A virus infection by preventing cytosolic entry. PLoS Pathog. 2011; 7:e1002337.
6. Bailey CC, Huang IC, Kam C, Farzan M. Ifitm3 limits the severity of acute influenza in mice. PLoS Pathog. 2012; 8:e1002909.
7. Desai TM, Marin M, Chin CR, Savidis G, Brass AL, Melikyan GB. IFITM3 restricts influenza A virus entry by blocking the formation of fusion pores following virus-endosome hemifusion. PLoS Pathog. 2014; 10:e1004048.
8. Zhang YH, Zhao Y, Li N, et al. Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals. Nat Commun. 2013; 4:1418.
9. Wang Z, Zhang A, Wan Y, et al. Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. Proc Natl Acad Sci USA. 2014; 111:769–774.
10. Mills TC, Rautanen A, Elliott KS, et al. IFITM3 and susceptibility to respiratory viral infections in the community. J Infect Dis. 2014; 209:1028–1031.
11. Gaio V, Nunes B, Pechirra P, et al. Hospitalization risk due to respiratory illness associated with genetic variation at IFITM3 in patients with influenza A(H1N1)pdm09 infection: a case-Control study. PLoS ONE. 2016; 11:e0158181.
12. Lopez-Rodriguez M, Herrera-Ramos E, Sole-Violan J, et al. IFITM3 and severe influenza virus infection. No evidence of genetic association. Eur J Clin Microbiol Infect Dis. 2016; 35:1811–1817.
13. Boon AC, deBeauchamp J, Hollmann A, et al. Host genetic variation affects resistance to infection with a highly pathogenic H5N1 influenza A virus in mice. J Virol. 2009; 83:10417–10426.
14. Belongia EA, Kieke BA, Donahue JG, et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis. 2009; 199:159–167.
15. Belongia EA, Kieke BA, Donahue JG, et al. Influenza vaccine effectiveness in Wisconsin during the 2007–08 season: comparison of interim and final results. Vaccine. 2011; 29:6558–6563.
16. Sundaram ME, McClure DL, VanWormer JJ, Friedrich TC, Meece JK, Belongia EA. Influenza vaccination is not associated with detection of noninfluenza respiratory viruses in seasonal studies of influenza vaccine effectiveness. Clin Infect Dis. 2013; 57:789–793.
17. Treanor JJ, Talbot HK, Ohmit SE, et al. Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. Clin Infect Dis. 2012; 55:951–959.
18. Ohmit SE, Thompson MG, Petrie JG, et al. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis. 2014; 58:319–327.
19. McCarty C, Wilke R, Giampietro P, Wesbrook S, Caldwell M. Marshfield Clinic Personalized Medicine Research Project (PMRP): design, methods and recruitment for a large population-based biobank. Personal Med. 2005; 2:49–79.
20. Roden DM, Pulley JM, Basford MA, et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther. 2008; 84:362–369.
21. McCarty CA, Chisholm RL, Chute CG, et al. The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med Genomics. 2011; 4:13.
22. Irving SA, Donahue JG, Shay DK, Ellis-Coyle TL, Belongia EA. Evaluation of self-reported and registry-based influenza vaccination status in a Wisconsin cohort. Vaccine. 2009; 27:6546–6549.
23. International HapMap Consortium. The international HapMap project. Nature. 2003; 426:789–796.
24. Turner SD, Berg RL, Linneman JG, et al. Knowledge-driven multi-locus analysis reveals gene-gene interactions influencing HDL cholesterol level in two independent EMR-linked biobanks. PLoS ONE. 2011; 6:e19586.
25. Van Driest SL, McGregor TL, Edwards Velez, et al. Genome-wide association study of serum creatinine levels during vancomycin therapy. PLoS ONE. 2015; 10:e0127791.
26. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007; 81:559–575.
27. Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. Am J Med. 2008; 121:258–264.
28. 1000 Genomes Consortium, Auton A, Brooks LD, et al. A global reference for human genetic variation. Nature. 2015; 526:68–74.
29. Kostova D, Reed C, Finelli L, et al. Influenza illness and hospitalizations averted by influenza vaccination in the United States, 2005-2011. PLoS ONE. 2013; 8:e66312.
30. Jia R, Xu F, Qian J, et al. Identification of an endocytic signal essential for the antiviral action of IFITM3. Cell Microbiol. 2014; 16:1080–1093.
31. John SP, Chin CR, Perreira JM, et al. The CD225 domain of IFITM3 is required for both IFITM protein association and inhibition of influenza A virus and dengue virus replication. J Virol. 2013; 87:7837–7852.
32. Jia R, Pan Q, Ding S, et al. The N-terminal region of IFITM3 modulates its antiviral activity by regulating IFITM3 cellular localization. J Virol. 2012; 86:13697–13707.
33. Chesarino NM, McMichael TM, Hach JC, Yount JS. Phosphorylation of the antiviral protein interferon-inducible transmembrane protein 3 (IFITM3) dually regulates its endocytosis and ubiquitination. J Biol Chem. 2014; 289:11986–11992.
34. Compton AA, Roy N, Porrot F, et al. Natural mutations in IFITM3 modulate post-translational regulation and toggle antiviral specificity. EMBO Rep. 2016; 17:1657–1671.
35. Randolph AG, Yip WK, Allen EK, et al. Evaluation of IFITM3 rs12252 association with severe pediatric influenza infection. J Infect Dis. 2017; 216:14–21.
36. Rothberg MB, Haessler SD. Complications of seasonal and pandemic influenza. Crit Care Med. 2010; 38:e91–e97.
37. Wrammert J, Smith K, Miller J, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature. 2008; 453:667–671.
38. Centers for Disease Control and Prevention. Estimates of deaths associated with seasonal influenza − United States, 1976–2007. MMWR Morb Mortal Wkly Rep. 2010; 59:1057–1062.
39. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004; 292:1333–1340.
40. Lee N, Cao B, Ke C, et al. IFITM3, TLR3, and CD55 gene SNPs and cumulative genetic risks for severe outcomes in Chinese patients with H7N9 / H1N1pdm09 influenza. J Infect Dis. 2017; 216:97–104.